Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Mycosis Fungoides 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia 3Congenital Abnormalities 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sezary Syndrome 2Sarcoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lung Neoplasms 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Colorectal Neoplasms 2Burkitt Lymphoma 2Breast Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

Rituximab 33Cyclophosphamide 23Filgrastim 18Peripheral Blood Stem Cell Transplantation 16Etoposide 13fludarabine phosphate 12Vincristine 12Prednisone 11Bortezomib 11sargramostim 10Radiotherapy 10Doxorubicin 8Cytarabine 8Cyclosporine 8Vorinostat 7Lenalidomide 7Cisplatin 7Biopsy 7tanespimycin 6Melphalan 6Magnetic Resonance Spectroscopy 6Ifosfamide 6bryostatin 1 5alvocidib 5aldesleukin 5Specimen Handling 5Methylprednisolone 5Methotrexate 5Interferon-alpha 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Lymphoma, Follicular × romidepsin × Clear all
NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00079443 2013-07-01

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
60 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00042822 2011-05-17

FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡